These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38710522)

  • 1. [Research progress on the differences between T and B cell responses to three different forms of human papilloma virus (HPV) vaccination].
    Peng Q; Li Y; Li J; Yao X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Apr; 40(4):378-382. PubMed ID: 38710522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
    Godi A; Bissett SL; Miller E; Beddows S
    PLoS One; 2015; 10(10):e0140926. PubMed ID: 26495976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
    Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
    Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diseases caused by human papilloma viruses].
    Zollner U; Schwarz TF
    Dtsch Med Wochenschr; 2011 May; 136(20):1067-72. PubMed ID: 21560109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
    Godi A; Panwar K; Haque M; Cocuzza CE; Andrews N; Southern J; Turner P; Miller E; Beddows S
    Vaccine; 2019 Apr; 37(18):2455-2462. PubMed ID: 30926298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papilloma virus (HPV) prevalence upon HPV vaccination in Swedish youth: a review based on our findings 2008-2018, and perspectives on cancer prevention.
    Du J; Ährlund-Richter A; Näsman A; Dalianis T
    Arch Gynecol Obstet; 2021 Feb; 303(2):329-335. PubMed ID: 33247317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPV vaccination and cervical cancer.
    Szarewski A
    Curr Oncol Rep; 2012 Dec; 14(6):559-67. PubMed ID: 22890794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Vaccination against human papilloma virus and cervical cancer].
    Kidon MI; Shechter E; Toubi E
    Harefuah; 2011 Jan; 150(1):33-6, 68. PubMed ID: 21449154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
    Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
    Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of clinical trials of human papillomavirus prophylactic vaccines.
    Schiller JT; Castellsagué X; Garland SM
    Vaccine; 2012 Nov; 30 Suppl 5(0 5):F123-38. PubMed ID: 23199956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
    Zhang Z; Zhang J; Xia N; Zhao Q
    Hum Vaccin Immunother; 2017 Oct; 13(10):2280-2291. PubMed ID: 28699820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic immunization with human papillomavirus vaccines induces oral immunity in mice.
    Ahn J; Peng S; Hung CF; Roden RBS; Best SR
    Laryngoscope; 2018 Jan; 128(1):E16-E20. PubMed ID: 28868617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
    Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours.
    Bubenik J
    Curr Cancer Drug Targets; 2008 May; 8(3):180-6. PubMed ID: 18473731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.
    Toft L; Storgaard M; Müller M; Sehr P; Bonde J; Tolstrup M; Østergaard L; Søgaard OS
    J Infect Dis; 2014 Apr; 209(8):1165-73. PubMed ID: 24273179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating CXCR5⁺CD4⁺ T Follicular-Like Helper Cell and Memory B Cell Responses to Human Papillomavirus Vaccines.
    Matsui K; Adelsberger JW; Kemp TJ; Baseler MW; Ledgerwood JE; Pinto LA
    PLoS One; 2015; 10(9):e0137195. PubMed ID: 26333070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Fox B; Scholar S; Rosen J; Chakhtoura N; Meric D; Dessy FJ; Datta SK; Descamps D; Dubin G;
    Hum Vaccin; 2011 Dec; 7(12):1343-58. PubMed ID: 22048173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.